State Street Corp Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

State Street Corp grew its stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 32.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,424 shares of the company’s stock after acquiring an additional 23,000 shares during the period. State Street Corp owned 0.21% of Checkpoint Therapeutics worth $212,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CKPT. Walleye Capital LLC bought a new stake in shares of Checkpoint Therapeutics during the 3rd quarter valued at $148,000. Gladstone Institutional Advisory LLC grew its holdings in Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 20,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares during the period. Magnus Financial Group LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 4,000 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics in the second quarter valued at approximately $295,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Trading Up 10.9 %

Shares of NASDAQ CKPT opened at $3.65 on Friday. The business has a 50-day moving average of $3.67 and a 200-day moving average of $2.81. The firm has a market capitalization of $178.24 million, a price-to-earnings ratio of -1.98 and a beta of 1.34. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, analysts predict that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. The trade was a 20.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total transaction of $744,377.40. Following the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital increased their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.